Belite Bio, Inc. ADR (BLTE) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Belite Bio, Inc. has reported promising results from its Phase 2 trial for Tinlarebant, showing potential to slow progression in degenerative retinal diseases like Stargardt Disease and Dry AMD. The company has initiated further Phase 3 trials, DRAGON and PHOENIX, to confirm these findings. Additionally, Belite Bio successfully raised $25 million in a registered direct offering to support its ongoing clinical programs.
For further insights into BLTE stock, check out TipRanks’ Stock Analysis page.
